Bill-Axelson A et al; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84. Abstract

Boehmer D et al; EORTC Radiation Oncology Group. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 2006;79(3):259-69. Abstract

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337(5):295-300. Abstract

D’Amico AV et al. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006;176(6 Pt 2):S11-5. Abstract

D’Amico AV et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292(7):821-7. Abstract

De Meerleer GO et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother Oncol 2007;[Epub ahead of print]. Abstract

Ficarra V et al. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 2006;98(6):1193-8. Abstract

Granfors T et al. Long-term follow-up of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006;176(2):544-7. Abstract

Hanks GE et al; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8. Abstract

Heymann JJ et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol 2007;25(1):77-84. Abstract

Holmberg L et al; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9. Abstract

Iversen P et al; Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median follow-up from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004;172(5 Pt 1):1871-6. Abstract

Kane CJ et al; SEARCH Database Study Group. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007;177(1):113-7. Abstract

Kibel AS et al. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy. Proc AUA 2006;Abstract 1589.

McLeod DG et al. Choices for definitive treatment of early-stage prostate cancer: Results from the COMPARE Registry. Proc AUA 2006;Abstract 1596.

McLeod DG et al. The bicalutamide 150 mg early prostate cancer program: Findings of the North American trial at 7.7-year median follow-up. J Urol 2006;176(1):75-80. Abstract

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8. Abstract

Milecki P et al. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: Perspective and therapeutic gain analysis. Neoplasma 2007;54(1):7-15. Abstract

Peeters ST et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990-6. Abstract

Pendleton J et al. Neoadjuvant therapy before radical prostatectomy: Where have we been? Where are we going? Urol Oncol 2007;25(1):11-8. Abstract

Ray ME et al. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 2006;68(6):1257-62. Abstract

Roach M 3rd et al; Radiation Therapy Oncology Group 9413. Phase III trial comparing whole pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21(10):1904-11. Abstract

Schroder FH et al; Members of the European Organisation for the Research and Treatment of Cancer Genitourinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846 — A phase III study. J Urol 2004;172(3):923-7. Abstract

Soloway MS et al; Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112-6. Abstract

Stone NN, Stock RG. Long-term disease free survival following prostate brachytherapy. Proc AUA 2006;Abstract 669.

Studer UE et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24(12):1868-76. Abstract

Taplin ME et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24(34):5408-13. Abstract

Thompson IM Jr et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006;296(19):2329-35. Abstract

Wirth MP et al; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70. Abstract

Wong YN et al. Treatment of localized prostate cancer: A survival analysis using SEER-Medicare data. Proc AUA 2006;Abstract 658.

Zapatero A et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 2005;23(27):6561-8. Abstract

Zhou P et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23(28):6992-8. Abstract

Zietman AL et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294(10):1233-9. Abstract